AbbVie Inc. (ABBV)
AbbVie is a global pharmaceutical giant that develops and sells medicines for complex conditions like immunology, oncology, and neuroscience.
Is AbbVie Inc. a good stock for a UK beginner?
The honest version: AbbVie is a global pharmaceutical giant that develops and sells medicines for complex conditions like immunology, oncology, and neuroscience.
Over about 2 years to 2026-07-31. This is the share price only - reinvesting the dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
A breakthrough in their research pipeline leads to a new blockbuster drug.
Failure to innovate, leading to a significant decline in market share.
What does AbbVie Inc. do?
AbbVie creates specialised drugs to treat chronic illnesses, making money by selling these treatments to healthcare providers and hospitals worldwide. They are well-known for their blockbuster immunology drugs, though they are currently working to diversify their range of treatments. Their fortunes hinge on growing newer medicines fast enough to replace the revenue from older products that have lost patent protection.
On our factor screen it looks strongest on momentum and growth, and weakest on income.
- ✓Pays a dividend - about 2.8% a year
- ✓Growing - revenue up about 10% over the year
- !High P/E of 71 - big growth is already priced in
- Growth screens high (73/100)
- Momentum screens high (73/100)
- High profit margins on core products
- Consistent history of paying dividends to shareholders
- Low volatility compared to the broader market
- Losing patent protection allows cheaper rivals to enter the market
- Strict government regulation on drug pricing
- High costs and uncertainty associated with developing new medicines
What do AbbVie Inc.'s numbers mean?
How much money does AbbVie Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does AbbVie Inc. pay a dividend?
Yes - AbbVie Inc. currently pays a dividend of about 2.8% a year (the yearly payout as a share of the price). A dividend is a slice of profit handed to shareholders; the yield moves as the price moves, and a company can cut or stop it.
When does AbbVie Inc. report earnings, and how did recent quarters go?
AbbVie Inc. is next scheduled to report on about 2026-10-29 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-07-31 | $3.61 | $3.65 | Beat +1% |
| 2026-04-29 | $2.67 | $2.65 | In line |
| 2026-02-04 | $2.65 | $2.71 | Beat +2% |
| 2025-10-31 | $1.78 | $1.86 | Beat +4% |
| 2025-07-31 | $2.91 | $2.97 | Beat +2% |
| 2025-04-25 | $2.40 | $2.46 | Beat +3% |
Across the last 6 quarters here, AbbVie Inc. came in ahead of what analysts expected 5 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for AbbVie Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of AbbVie Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- High profit margins on core products
- Consistent history of paying dividends to shareholders
- Low volatility compared to the broader market
- Significant drop in recent earnings growth
- Heavy reliance on a few key blockbuster drugs
- Complex business model that is difficult to value
- Losing patent protection allows cheaper rivals to enter the market
- Strict government regulation on drug pricing
- High costs and uncertainty associated with developing new medicines
The write-up's own warning lights — if these start happening, the case above changes.
- A major, unexpected failure in a late-stage clinical trial
- A sudden, drastic change in government healthcare policy regarding drug pricing
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.